TNFSF10 and glioblastoma: Glioblastoma multiforme (GBM) is a heterogeneous tumor, containing multiple genetically aberrant clones; it is the most common and aggressive malignant form of astrocytoma with a median survival of ~12–15 months.1, 2 In spite of improved surgical techniques and advanced radio/chemotherapy, the survival time of GBM patients has not been extended with any actual beneficial effect.3, 4 Recently, a promising therapeutic approach was introduced for GBM; selective induction of apoptosis using the pro-apoptotic cytokine tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).